ENSC Quote, Financials, Valuation and Earnings

IN8bio has a net margin of -- compared to Ensysce Biosciences's net margin of --. Ensysce Biosciences's return on equity of -- beat IN8bio's return on equity of --.

Ensysce Biosciences has a consensus price target of --, signalling upside risk potential of 1134.87%. On the other hand IN8bio has an analysts' consensus of -- which suggests that it could grow by 1879.17%. Given that IN8bio has higher upside potential than Ensysce Biosciences, analysts believe IN8bio is more attractive than Ensysce Biosciences.

Ensysce Biosciences has a beta of 0.598, which suggesting that the stock is 40.229% less volatile than S&P 500. In comparison IN8bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ensysce Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IN8bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences pays -- of its earnings as a dividend. IN8bio pays out -- of its earnings as a dividend.

Ensysce Biosciences quarterly revenues are --, which are smaller than IN8bio quarterly revenues of --. Ensysce Biosciences's net income of $661.8K is higher than IN8bio's net income of -$7.1M. Notably, Ensysce Biosciences's price-to-earnings ratio is -- while IN8bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences is -- versus -- for IN8bio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Ensysce Biosciences's net margin of -49.65%. Ensysce Biosciences's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Ensysce Biosciences has a consensus price target of --, signalling upside risk potential of 1134.87%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 620.92%. Given that Ensysce Biosciences has higher upside potential than NovaBay Pharmaceuticals, analysts believe Ensysce Biosciences is more attractive than NovaBay Pharmaceuticals.

Ensysce Biosciences has a beta of 0.598, which suggesting that the stock is 40.229% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Ensysce Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Ensysce Biosciences quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Ensysce Biosciences's net income of $661.8K is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Ensysce Biosciences's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences is -- versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Ensysce Biosciences's net margin of -2357.27%. Ensysce Biosciences's return on equity of -- beat Palatin Technologies's return on equity of --.

Ensysce Biosciences has a consensus price target of --, signalling upside risk potential of 1134.87%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1652.58%. Given that Palatin Technologies has higher upside potential than Ensysce Biosciences, analysts believe Palatin Technologies is more attractive than Ensysce Biosciences.

Ensysce Biosciences has a beta of 0.598, which suggesting that the stock is 40.229% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Ensysce Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Ensysce Biosciences quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. Ensysce Biosciences's net income of $661.8K is higher than Palatin Technologies's net income of -$7.8M. Notably, Ensysce Biosciences's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Sensei Biotherapeutics has a net margin of -- compared to Ensysce Biosciences's net margin of --. Ensysce Biosciences's return on equity of -- beat Sensei Biotherapeutics's return on equity of --.

Ensysce Biosciences has a consensus price target of --, signalling upside risk potential of 1134.87%. On the other hand Sensei Biotherapeutics has an analysts' consensus of -- which suggests that it could grow by 812.61%. Given that Ensysce Biosciences has higher upside potential than Sensei Biotherapeutics, analysts believe Ensysce Biosciences is more attractive than Sensei Biotherapeutics.

Ensysce Biosciences has a beta of 0.598, which suggesting that the stock is 40.229% less volatile than S&P 500. In comparison Sensei Biotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Ensysce Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sensei Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ensysce Biosciences pays -- of its earnings as a dividend. Sensei Biotherapeutics pays out -- of its earnings as a dividend.

Ensysce Biosciences quarterly revenues are --, which are smaller than Sensei Biotherapeutics quarterly revenues of --. Ensysce Biosciences's net income of $661.8K is higher than Sensei Biotherapeutics's net income of -$7.3M. Notably, Ensysce Biosciences's price-to-earnings ratio is -- while Sensei Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ensysce Biosciences is -- versus -- for Sensei Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.